Yahoo1d
Sammy Basso, activist who sought a cure for progeria, the rare aging condition from which he suffered
Sammy was thrilled when Pope Francis gave him a phone call. In 2007 he returned to the US for the first clinical trials of ...
Nature1mon
The Farnesyltransferase Inhibitors Tipifarnib and Lonafarnib Inhibit Cytokines Secretion in a Cellular Model of Mevalonate Kinase Deficiency
Farnesyltransferase inhibitors (FTIs) act at the end of mevalonate pathway. Two FTIs, Tipifarnib (Tip) and Lonafarnib (Lon), were therefore evaluated as possible therapeutical choices for the ...
Longest-Living Survivor Of Progeria Dies At 28; What Is This Rare Condition That Causes Rapid Ageing?
The treatment for this condition includes lonafarnib – which improves many aspects of progeria, including an increased ...
pharmaphorum2y
Gilead files first hepatitis delta therapy with FDA
Eiger's drug – called lonafarnib – is in a phase 3 trial (D-LIVR) that is now fully recruited and due to generate results by the end of next year. Lonafarnib is already approved in the US and ...
The New York Times26d
Sammy Basso, Advocate for Progeria Research, Is Dead at 28
Dr. Collins credited that medication, lonafarnib, which the Food and Drug Administration subsequently approved, with Mr. Basso’s relative longevity, along with the fact that he “took really ...
Hosted on MSN1mon
Sammy Basso, activist and longest-living survivor of progeria, dies at 28
although some adults will live into their early 20s. A drug called lonafarnib has been shown to slow down the progression of the disease.
Nature9mon
Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
The side-effect profile of FTIs in Phase I studies was diverse. Lonafarnib demonstrated primarily gastrointestinal toxicities (diarrhoea, nausea and vomiting), whereas tipifarnib's dose-limiting ...